^
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
PD-L1 expression
Gastric Adenocarcinoma
nivolumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
MET expression
Gastric Adenocarcinoma
AMG 102
Resistant: B - Late Trials
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant: B - Late Trials
HER-2 positive
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
CLDN18.2 expression
Gastric Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive: C3 – Early Trials
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
ATM mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ATR mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ATRX mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Gastric Adenocarcinoma
HER2 inhibitor
Resistant: C3 – Early Trials
Chr amplification(11)(q13)
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
MDM2 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
MDM4 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
CDKN2B deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
PD-L1 expression
Gastric Adenocarcinoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
Gastric Adenocarcinoma
atezolizumab
Sensitive: C3 – Early Trials
MET amplification
Gastric Adenocarcinoma
RG3638
Sensitive: C4 – Case Studies
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant: C4 – Case Studies
FGFR2 amplification
Gastric Adenocarcinoma
TAS 120
Sensitive: D – Preclinical
FGFR2 amplification
Gastric Adenocarcinoma
nintedanib
Sensitive: D – Preclinical